PharmEasy's Thyrocare Pledge: 10% Paid Back, 90% Still Hanging Over the Stock

Background: How It Started

When API Holdings Limited — the parent company of PharmEasy — was scrambling for survival in 2024-25, it pledged shares of its most valuable listed asset to raise cash.

That asset was Thyrocare Technologies Limited, India's largest diagnostics chain. A profitable, cash-generating business that API had acquired from its founder A. Velumani in 2021 for ₹4,546 crore — at the peak of the startup bull market.

The pledge was significant. 9,69,69,696 shares — 60.93% of Thyrocare's total equity — were encumbered in favour of Catalyst Trusteeship Limited as security against a ₹1,200 Crore NCD (Non-Convertible Debenture) issuance but now ir remains only 1050 crore because company redeemed 150 cr worth of debentures from the market.. 

The debenture holders included 360 One Prime (₹249.75 Cr), Micro Labs (₹226.62 Cr), Tata Capital (₹112.50 Cr), Bennett Coleman & Company, J Kumar Infraprojects, and over 25 other investors.

A) What Has Changed?

On March 30, 2026, API Holdings made its first meaningful move toward reducing this debt.

The company partially redeemed its Series 1 NCDs by paying ₹150 Crore, reducing the face value per debenture from ₹10,00,000 to ₹9,00,000.

On March 31, 2026, Docon Technologies Private Limited — the promoter entity holding Thyrocare shares — filed an updated disclosure with NSE and BSE under SEBI SAST Regulation 31.

Current Status

Key Insight: 10% of the debt has been repaid, but no shares have been released from pledge yet.

B) Why This Matters for Investors

A 60.93% promoter pledge is a major red flag in equity investing.

As long as promoter shares remain pledged, any stress event at API Holdings — such as missed payments, credit downgrades, or liquidity issues — allows debenture holders to invoke the pledge and sell shares in the open market.

This kind of forced selling can significantly impact stock prices and hurt minority shareholders.

While the ₹150 Crore repayment indicates progress, ₹1,050 Crore still remains outstanding, keeping the overhang intact.

Until the pledge percentage drops meaningfully (ideally below 30%), this risk will continue to weigh on investor sentiment.

C) The Bigger Picture: PharmEasy's Comeback Journey

API Holdings represents one of India's most notable startup cautionary tales.

After raising significant capital during the 2020-21 boom and acquiring Thyrocare at a premium valuation, the company faced challenges as profitability lagged and funding conditions tightened.

The Thyrocare pledge reflects this stress — using a strong asset to secure liquidity.

The Positive: Thyrocare remains a fundamentally strong, profitable business.

The Concern: The promoter's financial position continues to cast a shadow over the stock.

D) What to Watch Going Forward

Investors should closely monitor:

• Quarterly NCD repayments

• Reduction in pledged shares

• Any changes in credit ratings

Each repayment milestone brings Thyrocare closer to a cleaner promoter structure — which could lead to a potential re-rating of the stock.

 

Source: SEBI SAST Regulation 31 disclosure filed by Docon Technologies Private Limited on March 31, 2026.

This article is for informational purposes only and does not constitute investment advice.